2,6,7-Substituted Purines as HDM2 Inhibitors for Cancer Therapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for effective inhibitors of the HDM2 or MDM2 protein to treat or prevent cancer and other diseases associated with cell proliferation, as current therapies have limitations in targeting the p53-MDM2 interaction effectively.
Innovation Solution
Development of novel 2,6,7 substituted purine compounds that act as HDM2 or MDM2 antagonists, which can inhibit or antagonize the HDM2-p53 interaction, thereby activating p53 proteins in cells and treating diseases associated with abnormal cell proliferation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current therapies are used to target p53-MDM2 interaction, then treatment of cancer is attempted, but the therapies have limitations in effectively inhibiting the HDM2-p53 interaction
Solution Approach 1:
The patent employs parameter changes by modifying the chemical structure of purine compounds with specific substitutions at positions 2, 6, and 7. These structural parameter changes enable the compounds to effectively inhibit the HDM2-p53 interaction, overcoming the limitations of current therapies while maintaining reliable cancer treatment potential
Solution Approach 2:
The invention uses composite molecular structures combining purine core with various substituent groups (aryl, heteroaryl, alkyl, etc.) to create compounds with enhanced HDM2 inhibitory activity. This composite approach allows the molecules to effectively disrupt the p53-MDM2 interaction that current therapies fail to address
2Productivity
If HDM2-p53 interaction is inhibited, then tumor proliferation is slowed and apoptosis is induced, but the need for effective inhibitors indicates current options are insufficient
Solution Approach 1:
The patent segments the HDM2 binding interface by designing purine compounds with specific substituent patterns at positions 2, 6, and 7 that target different regions of the HDM2 protein. This segmentation strategy enables effective disruption of the p53-MDM2 interaction, achieving high anti-tumor efficacy where previous inhibitors failed
Solution Approach 2:
The purine compounds act as intermediary molecules that bind to HDM2 and prevent its interaction with p53. These intermediary compounds effectively block the harmful p53-MDM2 interaction, inducing apoptosis and slowing tumor proliferation, thereby addressing the unmet need for reliable HDM2 inhibitors
Data Source
AI summary
The present invention provides 2,6,7 substituted purines as described herein or a pharmaceutically acceptable salt thereof. The representative compounds are useful as inhibitors of the HDM2 protein. Also disclosed are pharmaceutical compositions comprising the above compounds and potential methods of treating cancer using the same.